ADPT Adaptive Biotechnologies Corp
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1478320 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY17.9%
TTM net income YoY11.4%
TTM EPS YoY13.5%
Revenue 3-yr CAGR18.4%
Net income 3-yr CAGR—
Margins
Gross margin74.2%
Operating margin-16.2%
Net margin-23.7%
FCF margin-3.0%
EBITDA margin-11.6%
Returns
ROE-37.1%
ROA-12.0%
ROIC (approx.)-19.9%
Asset turnover0.51x
Leverage & solvency
Liabilities / assets73.1%
Debt / equity0.00x
Current ratio3.97x
Interest coverage-5.33x
Cash quality & payout
Operating cash flow / net income0.06x
Accruals ratio-11.3%
Payout ratio—
Capex / revenue1.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $83.90M | $71.55M | $70.87M | $71.68M | $93.97M | $58.88M | $52.44M | $47.46M |
| Cost of revenue | $19.93M | $20.16M | $18.71M | $18.22M | $18.16M | $18.00M | $16.98M | $18.05M |
| Gross profit | $63.97M | $51.39M | $52.17M | $53.46M | $75.82M | $40.88M | $35.46M | $29.41M |
| R&D expense | $18.64M | $19.15M | $23.62M | $21.76M | $23.67M | $24.13M | $24.20M | $23.19M |
| SG&A expense | $18.46M | $21.17M | $20.98M | $19.56M | $17.96M | $17.79M | $17.40M | $18.06M |
| Operating income | -$457,000 | -$15.77M | -$19.21M | -$12.77M | $10.29M | -$25.04M | -$29.60M | -$33.84M |
| Interest expense | $503,000 | $2.69M | $2.89M | $2.95M | $2.97M | $2.95M | $2.90M | $2.95M |
| Net income | $2.88M | -$39.79M | -$20.03M | -$13.58M | $9.55M | -$25.61M | -$29.85M | -$33.69M |
| EBITDA | $2.72M | -$12.47M | -$15.82M | -$9.14M | $14.26M | -$20.96M | -$25.32M | -$29.91M |
| EPS (basic) | 0.02 | -0.25 | -0.13 | — | 0.06 | -0.17 | -0.20 | — |
| EPS (diluted) | 0.02 | -0.25 | -0.13 | — | 0.06 | -0.17 | -0.20 | — |
| Weighted avg. shares (diluted) | 186.88M | 159.86M | 155.52M | — | 163.16M | 152.08M | 149.20M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $75.61M | $169.87M | $77.58M | $70.50M | $55.03M | $43.16M | $50.65M | $47.92M |
| Short-term investments | $223.34M | $174.38M | $140.75M | $156.49M | $157.74M | $154.71M | $142.78M | $174.37M |
| Receivables | $66.67M | $49.51M | $48.31M | $50.37M | $44.82M | $44.28M | $43.58M | $41.73M |
| Inventory | $10.05M | $10.50M | $11.21M | $9.82M | $9.93M | $8.40M | $8.68M | $8.44M |
| Current assets | $392.69M | $420.56M | $291.81M | $300.19M | $281.44M | $261.86M | $256.49M | $283.75M |
| PP&E, net | $27.97M | $29.45M | $30.77M | $34.11M | $37.50M | $41.05M | $44.43M | $48.62M |
| Goodwill | $118.97M | $118.97M | $118.97M | $118.97M | $118.97M | $118.97M | $118.97M | $118.97M |
| Intangibles | $456,000 | $884,000 | $1.31M | $1.73M | $2.15M | $2.58M | $3.01M | $3.42M |
| Total assets | $683.12M | $640.68M | $505.94M | $512.74M | $490.61M | $496.64M | $510.85M | $539.38M |
| Current liabilities | $98.97M | $87.71M | $87.01M | $89.92M | $83.36M | $92.14M | $87.81M | $98.05M |
| Short-term debt | $0 | $0 | $5.80M | $4.64M | $2.43M | $3.07M | $2.01M | $865,000 |
| Long-term debt | $0 | $0 | $124.75M | $126.57M | $129.41M | $130.50M | $131.55M | $132.41M |
| Total debt | $0 | $0 | $130.55M | $131.21M | $131.84M | $133.56M | $133.56M | $133.28M |
| Total liabilities | $499.23M | $490.02M | $281.70M | $287.74M | $286.36M | $317.10M | $320.63M | $336.89M |
| Shareholders' equity | $176.21M | $142.91M | $216.34M | $218.79M | $204.44M | $179.72M | $190.42M | $202.71M |
| Net debt | -$75.61M | -$169.87M | $52.97M | $60.71M | $76.80M | $90.40M | $82.92M | $85.36M |
| Shares outstanding | 161.57M | 159.06M | 159.70M | 153.78M | 152.58M | 152.23M | 151.92M | 147.77M |
| Cash flow statement | ||||||||
| Operating cash flow | $9.61M | -$6.40M | -$9.54M | $2.06M | -$7.13M | -$12.43M | -$28.48M | -$12.49M |
| Capital expenditure | $1.93M | $1.18M | $796,000 | $636,000 | $409,000 | $655,000 | $1.26M | $80,000 |
| Free cash flow | $7.68M | -$7.58M | -$10.33M | $1.42M | -$7.54M | -$13.09M | -$29.74M | -$12.57M |
| Investing cash flow | -$125.06M | -$43.48M | $9.14M | -$8.25M | $17.28M | $3.35M | $25.57M | $22.12M |
| Financing cash flow | $21.17M | $142.19M | $7.50M | $21.66M | $1.68M | $1.61M | $5.45M | $127,000 |
| Depreciation & amortization | $3.18M | $3.30M | $3.39M | $3.63M | $3.97M | $4.07M | $4.29M | $3.93M |
| Stock-based compensation | $10.39M | $11.12M | $11.93M | $12.72M | $13.26M | $13.36M | $12.15M | $12.83M |
| Share buybacks | $0 | — | — | — | $0 | — | — | — |
Free plan shows the latest 8 periods; Pro shows all 34 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.